WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
Press Releases
March 25, 2025

WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoYAdjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9

bradford

The Bradford Era

Local & Social